PQ6 Stock Overview A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Starpharma Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Starpharma Holdings Historical stock prices Current Share Price AU$0.059 52 Week High AU$0.10 52 Week Low AU$0.04 Beta 0.75 1 Month Change -4.80% 3 Month Change 17.82% 1 Year Change -27.44% 3 Year Change -91.38% 5 Year Change -92.07% Change since IPO -88.56%
Recent News & Updates
Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024 Oct 03
Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023) Aug 23
First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023) Mar 04 Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024
Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023 Oct 02
Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses Sep 19 See more updates
Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024 Oct 03
Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023) Aug 23
First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023) Mar 04 Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024
Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023 Oct 02
Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses Sep 19
No independent directors Sep 05
Starpharma Holdings Limited Announces Change of Company Secretary Aug 28
New minor risk - Market cap size Jun 23
New minor risk - Share price stability Jun 14
Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer Jun 09
First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022) Feb 28
Starpharma Holdings Limited Announces Board Changes Feb 02
Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023 Jan 31 Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary
Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia Dec 16
Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca Dec 14
Starpharma Holdings Limited Announces Management Changes Nov 30
Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau Nov 21 Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022 Sep 30
Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO Sep 13
Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer Sep 12
Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021) Aug 26
Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model Jul 20
Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray May 19
Starpharma Holdings Limited Appoints Jeff Davies as Director Apr 03 Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK
Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron Mar 03
Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022 Feb 24
First half 2022 earnings: EPS in line with expectations, revenues disappoint Feb 22
Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel Nov 25
Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel Sep 16
Independent Non-Executive Director recently bought €44k worth of stock Sep 02
Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020) Aug 26
Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo Aug 25
Independent Non-Executive Deputy Chairman Peter Turvey has left the company Aug 04
Starpharma Releases New Data About SPL7013 Jun 18
Forecast to breakeven in 2022 Jun 12
Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India Jun 11
Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus Jun 01
Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model Mar 17
Starpharma Signs DEP ADC Research Agreement with MSD Feb 13
Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion Feb 09
New 90-day high: €1.00 Feb 04
New 90-day high: €0.98 Dec 29
New 90-day low: €0.76 Dec 08
Starpharma Holdings Limited Announces Board Changes Nov 20
Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray Nov 19
Starpharma Holdings Limited announced that it has received AUD 45 million in funding Oct 06
Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding Sep 30
Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv Sep 26
New 90-day high - €1.05 Sep 15
Full year earnings released - €0.04 loss per share Aug 28
New 90-day high - €0.77 Aug 26 Shareholder Returns PQ6 DE Pharmaceuticals DE Market 7D 4.4% 2.5% 1.3% 1Y -27.4% -15.2% 9.0%
See full shareholder returns
Return vs Market: PQ6 underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is PQ6's price volatile compared to industry and market? PQ6 volatility PQ6 Average Weekly Movement 14.1% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PQ6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PQ6's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
Show more Starpharma Holdings Limited Fundamentals Summary How do Starpharma Holdings's earnings and revenue compare to its market cap? PQ6 fundamental statistics Market cap €27.59m Earnings (TTM ) -€4.90m Revenue (TTM ) €5.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PQ6 income statement (TTM ) Revenue AU$9.76m Cost of Revenue AU$10.69m Gross Profit -AU$929.00k Other Expenses AU$7.24m Earnings -AU$8.16m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.02 Gross Margin -9.52% Net Profit Margin -83.69% Debt/Equity Ratio 2.8%
How did PQ6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 12:26 End of Day Share Price 2025/01/10 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Starpharma Holdings Limited is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dennis Hulme APP Securities Pty Ltd. Tanushree Jain Bell Potter Matthijs Smith Canaccord Genuity
Show 9 more analysts 
